Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
The Lancet. Oncology|July 13, 2019
The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysisJoseph C Del Paggio, Ian F Tannock
Internal Medicine Journal|May 16, 2017
Disturbances in blood flow and 'medicine's greatest imitator'Joseph C Del Paggio, Scott Bradshaw, Laura Marcotte
Journal of the National Cancer Institute|February 25, 2025
Proportion of patients in phase 2 oncology trials receiving treatments that are ultimately approvedCharlotte Ouimet, Bianca Fodor, Joseph C Del Paggio, et al.
Journal of Clinical Epidemiology|February 15, 2026
Drug Approvals in Crowded Drug Classes Potentially Reflect Efficacy Over-Estimates and False Positivity: A Portfolio Analysis of Immune Checkpoint Inhibitor TrialsBenjamin Gregory Carlisle, Mithat Gönen, Luciano Fernandez, et al.
Scientific Reports|September 26, 2023
Large numbers of patients are needed to obtain additional approvals for new cancer drugs: A retrospective cohort studyCharlotte Ouimet, Nora Hutchinson, Catherine Wang, et al.
JNCI Cancer Spectrum|July 31, 2019
Reliability of Oncology Value Framework Outputs: Concordance Between Independent Research GroupsJoseph C Del Paggio, Sierra Cheng, Christopher M Booth, et al.
Journal of Clinical Epidemiology|April 7, 2023
Bypassing phase 2 in cancer drug development erodes the risk/benefit balance in phase 3 trialsHannah Moyer, Merlin Bittlinger, Angela Nelson, et al.
JAMA Oncology|March 25, 2021
Evolution of the Randomized Clinical Trial in the Era of Precision OncologyJoseph C Del Paggio, John S Berry, Wilma M Hopman, et al.
The Lancet. Oncology|March 28, 2024
Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional studyJoseph C Del Paggio, Rohini Naipaul, Scott Gavura, et al.
The Lancet. Oncology|June 7, 2017
Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworksJoseph C Del Paggio, Richard Sullivan, Deborah Schrag, et al.
Pageof 2